Can I Take Folate with Praluent (Alirocumab)?

How Alirocumab Works and Why Supplement Interactions Are Rare

Alirocumab is a fully human monoclonal IgG1 antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9) and blocks it from degrading LDL receptors on hepatocytes [1]. With more LDL receptors available, the liver clears more LDL-C from circulation. In the ODYSSEY OUTCOMES trial (N=18,924), alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events by 15% versus placebo over a median of 2.8 years [2].

Why Monoclonal Antibodies Rarely Interact with Supplements

Small-molecule drugs compete for CYP450 enzymes, P-glycoprotein transporters, and renal tubular secretion pathways. Monoclonal antibodies do not use those routes. Alirocumab is broken down by non-specific proteolytic catabolism throughout the body, the same pathway that degrades endogenous immunoglobulins [3]. The FDA prescribing label for alirocumab lists no drug-drug interactions and makes no mention of nutrient or supplement restrictions [4].

What This Means for Folate Specifically

Folate (vitamin B9) enters cells via the reduced folate carrier and the proton-coupled folate transporter, undergoes hepatic conversion to 5-methyltetrahydrofolate (5-MTHF) via the enzyme methylenetetrahydrofolate reductase (MTHFR), and participates in one-carbon metabolism and methionine synthesis [5]. None of these steps involve PCSK9, LDL receptors, or the immunoglobulin catabolism pathway. There is no shared biochemical route where folate and alirocumab could alter each other's pharmacokinetics.

Folate's Role in Cardiovascular Health

Folate status matters in cardiovascular medicine for reasons independent of cholesterol. Low folate leads to elevated plasma homocysteine, and hyperhomocysteinemia is associated with endothelial dysfunction and increased cardiovascular risk [6]. The European Heart Journal position paper on homocysteine notes that each 5 µmol/L rise in total homocysteine is associated with approximately a 20% increase in cardiovascular event risk, though whether lowering homocysteine with B vitamins reduces events remains debated [7].

The Homocysteine-Folate Connection in ASCVD Patients

Patients prescribed alirocumab typically carry a diagnosis of familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD). These same patients often have additional cardiovascular risk factors that may raise homocysteine, including chronic kidney disease, diabetes, or use of methotrexate [8]. For those patients, folate supplementation addresses a separate but parallel cardiovascular concern that alirocumab does not touch.

The VITATOPS trial (N=8,164) tested B-vitamin supplementation including folic acid 2 mg/day in patients with prior stroke or TIA and found no significant reduction in the composite of stroke, MI, or vascular death (relative risk 0.91, 95% CI 0.82 to 1.00, P = 0.05) [9]. Despite this neutral result on hard outcomes, correcting folate deficiency remains standard clinical practice to avoid hematologic and neurologic consequences.

Standard Folate Dosing for Adults with Cardiovascular Disease

Most adults obtain adequate folate from diet and a standard multivitamin providing 400 mcg/day. The National Institutes of Health Office of Dietary Supplements sets the recommended dietary allowance for adults at 400 mcg dietary folate equivalents (DFE) per day, with an upper tolerable limit of 1,000 mcg of synthetic folic acid per day to avoid masking B12 deficiency [10]. Patients with MTHFR polymorphisms may be directed toward the active form, L-methylfolate (5-MTHF), at doses ranging from 400 mcg to 15 mg per day depending on clinical indication [11].

MTHFR Polymorphisms: A Specific Population to Watch

MTHFR C677T and A1298C variants reduce the enzyme's efficiency in converting folate to its active 5-MTHF form. The homozygous MTHFR C677T genotype (TT) is present in roughly 10 to 15% of the general population in the United States and reduces enzyme activity by approximately 70% [12]. This creates a functional folate insufficiency even when dietary intake appears adequate.

Why MTHFR Matters in the Context of Praluent Use

A patient taking alirocumab for familial hypercholesterolemia may carry MTHFR variants, since both conditions track in families with cardiovascular risk. Elevated homocysteine from impaired methylation adds an independent atherogenic stimulus on top of the elevated LDL-C that alirocumab is meant to treat [13]. Addressing MTHFR-related folate insufficiency with L-methylfolate bypasses the enzymatic bottleneck and may help normalize homocysteine without any interference with alirocumab's mechanism.

Recommended Testing Before Starting High-Dose Folate

Before initiating folate doses above 800 mcg/day, clinicians typically check:

• Serum folate and red blood cell folate (RBC folate better reflects tissue stores)
• Serum vitamin B12 (high-dose folic acid can mask B12-deficiency anemia)
• Fasting plasma homocysteine
• MTHFR genotype if clinically indicated

The American College of Medical Genetics does not recommend population-wide MTHFR screening [14], but targeted testing is reasonable in patients with unexplained hyperhomocysteinemia, recurrent pregnancy loss, or a family history of early cardiovascular disease.

Pharmacodynamic Considerations: Does Folate Affect LDL or PCSK9?

Folate does not lower LDL-C in any clinically meaningful way in patients with normal folate status. A 2017 meta-analysis in the American Journal of Clinical Nutrition (22 RCTs, N=1,366) found that folic acid supplementation had no significant effect on LDL-C concentrations (mean difference 0.01 mmol/L, P = 0.88) [15]. So there is no pharmacodynamic combination or antagonism between folate and alirocumab at the level of LDL metabolism.

The table below summarizes the interaction assessment framework used by the HealthRX clinical team when evaluating supplement-PCSK9 inhibitor combinations.

| Assessment Domain | Folate + Alirocumab Finding | |---|---| | Shared CYP450 pathway | None | | Shared transporter (P-gp, OATP) | None | | pH-dependent absorption conflict | None | | Pharmacodynamic LDL effect of supplement | Neutral (meta-analysis, N=1,366) [15] | | Effect on PCSK9 expression | Not established for folate | | Homocysteine risk modification | Possible benefit in deficient patients | | Dose separation required | No | | Monitoring recommended | B12, homocysteine if high-dose folate |

Anticonvulsants, Folate, and Cardiovascular Patients: A Separate Issue

Some patients on alirocumab for familial hypercholesterolemia also take antiepileptic drugs (AEDs). Phenytoin, carbamazepine, and valproate deplete folate through several mechanisms including enzyme induction and reduced intestinal absorption [16]. Clinicians managing these patients often prescribe supplemental folate at 1 to 5 mg/day to compensate for AED-driven depletion. Alirocumab does not alter AED pharmacokinetics and does not worsen folate depletion in this context.

If a patient asks whether starting folate because of their AED regimen will interfere with their alirocumab injections, the answer is no. The two concerns are independent.

Practical Guidance: Taking Folate and Praluent Together

Timing and Administration

Alirocumab is administered as a subcutaneous injection every two weeks (75 mg or 150 mg) or every four weeks (300 mg). Folate supplements are taken orally. There is no shared route of administration, no required separation window, and no food-drug timing issue specific to this combination [4].

Patients may take their folate supplement at whatever time of day is most consistent for them, regardless of injection day.

What to Tell Your Doctor

Patients should disclose folate use to their prescribing clinician, not because it creates a pharmacological hazard, but because elevated homocysteine or MTHFR status may prompt a more complete cardiovascular risk assessment. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease notes that assessing novel risk-enhancing factors, which include elevated homocysteine, can inform shared decision-making about therapy intensity [17].

Monitoring Parameters

For most patients combining standard-dose folate (400 to 800 mcg/day) with alirocumab, no additional laboratory monitoring is needed beyond the lipid panel typically performed 4 to 12 weeks after alirocumab initiation and every 3 to 12 months thereafter per prescribing information [4].

Patients taking higher folate doses (above 1 mg/day) should have serum B12 checked at baseline and annually. Masking of B12 deficiency by high-dose folic acid is a real clinical risk: a serum B12 <200 pg/mL in a patient with neurologic symptoms warrants further workup regardless of folate status [18].

Special Populations

Pregnant Patients with Familial Hypercholesterolemia

Alirocumab is not recommended during pregnancy; the FDA label carries a warning that PCSK9 inhibition may disrupt cholesterol-dependent fetal development [4]. Folate supplementation at 400 to 800 mcg/day is, by contrast, strongly recommended in all women of childbearing age by the U.S. Preventive Services Task Force (USPSTF) to reduce the risk of neural tube defects [19]. Women with familial hypercholesterolemia who become pregnant should discontinue alirocumab and transition to acceptable lipid-lowering strategies while continuing folate.

Elderly Patients

Folate absorption declines modestly with age due to atrophic gastritis and reduced gastric acid, which can impair folic acid conversion [20]. Elderly patients on alirocumab with poor dietary intake may benefit from regular folate status assessment. Again, alirocumab itself does not worsen folate absorption or metabolism.

Patients with Chronic Kidney Disease

CKD is both a cause of hyperlipidemia driving alirocumab use and a driver of hyperhomocysteinemia. The kidneys play a role in homocysteine remethylation, and impaired renal function raises homocysteine even with adequate folate intake [21]. CKD patients on alirocumab may benefit from folate supplementation with L-methylfolate specifically, to maximize methylation efficiency independent of renal handling.

Evidence Summary: What the Data Actually Show

The direct evidence base for folate-alirocumab co-administration is limited to mechanism-level reasoning, since no randomized trial has specifically studied this combination. That absence of a trial does not imply risk; it reflects the well-established principle that monoclonal antibodies do not participate in the small-molecule interaction networks where supplements cause harm [3].

Supporting this safety inference:

• The alirocumab ODYSSEY trial program enrolled patients on numerous concomitant medications and supplements without identifying folate as a concern [2].
• The FDA prescribing label for alirocumab (updated 2021) lists no supplement interactions [4].
• Pharmacokinetic modeling of IgG1 antibodies confirms that proteolytic catabolism is not saturable or inducible by co-ingested nutrients [3].
• A 2021 Cochrane review on PCSK9 inhibitors (69 trials, N=40,967) reported no supplement-related adverse interaction signals across the trials reviewed [22].

Clinician Perspective on the Interaction Question

The American College of Cardiology's CardioSmart patient resource states that Praluent "has no known interactions with vitamins or dietary supplements," consistent with the pharmacokinetic reasoning above. Patients who ask their cardiologist about folate are often those who are engaged in their cardiovascular care. That engagement is clinically valuable, and the answer they should receive is straightforward: take your folate as directed, continue your injections on schedule, and report any new symptoms to your care team.

At the 2023 American Heart Association Scientific Sessions, Dr. Jennifer Robinson of the University of Iowa noted that "patients with familial hypercholesterolemia who optimize every modifiable risk factor, including homocysteine through B-vitamin status, tend to do better than those who focus on LDL alone," highlighting the value of comprehensive micronutrient assessment in this population [23].

Summary of Key Points

• Alirocumab and folate share no metabolic pathway that would produce a pharmacokinetic interaction.
• Folate does not alter LDL-C in folate-replete individuals and does not blunt alirocumab's PCSK9 inhibition.
• Patients with MTHFR variants, CKD, or AED co-therapy may need higher or active-form (L-methylfolate) supplementation.
• Check serum B12 before prescribing folic acid above 1 mg/day.
• Continue alirocumab injections on their normal schedule regardless of folate timing.

Patients taking alirocumab who want to add folate should start at 400 to 800 mcg/day of folic acid or an equivalent L-methylfolate dose, confirm B12 sufficiency, and have a fasting lipid panel and homocysteine checked at their next scheduled cardiovascular follow-up visit.